Loading organizations...
N99 develops plant-based sports nutrition products, emphasizing organic, natural ingredients. The company offers protein powders, notably pioneering Europe's first matcha protein. Formulated with organic pea and rice proteins, these deliver essential amino acids, vitamins, and minerals, providing clean, high-quality nutritional support for active lifestyles.
Nicholas Orsini founded N99 in 2019, recognizing a market need for transparent, clean-label nutrition. He sought to counter supplements laden with sugars and fillers, offering products crafted from natural components. This insight guided their distinctive matcha protein development, establishing a core philosophy for ingredient integrity.
N99 caters to consumers prioritizing natural, effective solutions for enhancing health and performance. The company’s mission is to redefine nutritional approaches by delivering premium, plant-based options. Its vision centers on continuously elevating well-being through innovative, high-integrity products.
N99 has raised $1.2M across 2 funding rounds.
N99 has raised $1.2M in total across 2 funding rounds.
N99 has raised $1.2M in total across 2 funding rounds.
N99's investors include Inovexus, Clement Benoit.
N99 has raised $1.2M across 2 funding rounds. Most recently, it raised $1.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $1M Seed | — | Inovexus | Announced |
| May 1, 2021 | $210K Seed | — | Inovexus, Clement Benoit | Announced |
99 Technologies is a Swiss-based technology company specializing in innovative disinfection solutions for surfaces and medical devices, targeting Healthcare Acquired Infections (HCAI) and broader public health needs.[1] It offers automated room and targeted surface disinfection systems that emphasize efficacy, efficiency, flexibility, short cycles, compliance, ease of use, portability, and cost-effectiveness, serving healthcare facilities and public spaces to minimize contamination risks and maximize ROI.[1]
The company addresses critical gaps in infection prevention, particularly against resistant pathogens like bacteria, viruses, fungi, and spores, with products proven effective beyond routine methods; the COVID-19 pandemic amplified demand by highlighting needs in both clinical and public environments.[1]
99 Technologies emerged in Switzerland with a focused mission to combat HCAI by developing advanced disinfection technologies, driven by the need for continuous, efficient processes in clinical settings to prevent unnecessary losses.[1] The COVID-19 pandemic served as a pivotal moment, raising global awareness and extending the company's relevance to public spaces beyond hospitals.[1]
While specific founding year and founder details are not detailed in available sources, the company's backstory centers on recognizing pathogens' defense mechanisms that evade standard disinfections, leading to innovative formulations for broad-spectrum protection.[1]
99 Technologies rides the wave of infection prevention tech, amplified by post-COVID awareness of surface transmission in healthcare and public spaces, where HCAI remains a persistent global challenge.[1] Timing is ideal amid rising antimicrobial resistance and demands for non-chemical, automated disinfection amid labor shortages in cleaning protocols.[1]
Market forces like regulatory pushes for HCAI reduction and public health investments favor its portable, efficient systems, influencing the ecosystem by setting benchmarks for broad-spectrum efficacy and ease, potentially expanding to smart IoT-integrated disinfection in hospitals and transit hubs.[1]
Next for 99 Technologies involves scaling beyond Europe into global markets, integrating AI for predictive disinfection and expanding formulations against emerging pathogens.[1] Trends like antimicrobial resistance, climate-driven outbreaks, and hybrid work/public space hygiene will shape its path, evolving its influence from niche HCAI fighter to essential player in resilient infrastructure.[1] This positions it to sustain the safety innovations sparked by pandemic urgency, delivering lasting impact where contamination threats persist.
